A Vaccine to Stop Cancer Before It Starts? Plus Arena's $3.1B Scoreboard | Tech Arcade Podcast

Swiss biotech Nouscom has raised 120 million euros to test NOUS-209, an off-the-shelf vaccine meant to stop cancer before it starts in people with Lynch syndrome. Then Arena, the site where you vote between two anonymous chatbots, is now valued at 3.1 billion dollars: how it works, how it makes money, and the catch.

Full story: https://www.techarcade.io/this-cancer-prevention-vaccine-kept-every-patient-clear-of-colon-cancer-and-just-raised-13/

Full story: https://www.techarcade.io/the-website-that-ranks-ai-models-is-now-worth-3-1-billion/

Sources

https://www.globenewswire.com/news-release/2026/10/19/3382989/0/en/nouscom-raises-120-million-135-million-in-oversubscribed-series-d-financing-and-will-present-long-term-cancer-interception-clinical-data-in-lynch-syndrome-carriers-at-esmo.html

https://www.mdanderson.org/newsroom/research-newsroom/2026/01/immune-targeting-vaccine-shows-promise-intercepting-cancer-in-pa.html

https://www.mdanderson.org/cancerwise/qa-understanding-and-managing-lynch-syndrome.h00-158589789.html

https://www.fiercebiotech.com/biotech/nouscom-raises-135m-pivotal-trial-cancer-preventing-vaccine-candidate

https://techcrunch.com/2026/10/08/popular-ai-leaderboard-arena-nearly-doubles-valuation-to-3-1b-valuation-in-10-months/

https://www.felicis.com/blog/founder-profile-arenas-Anastasios-Angelopoulos-and-Wei-Lin-Chiang

Note: the "free of advanced adenomas and colorectal cancer" result comes from Nouscom's ESMO 2026 abstract; MD Anderson's January summary of the Nature Medicine paper reports fewer precancerous lesions and no new advanced polyps at one year.

More at https://www.techarcade.io

#techarcade #podcast #biotech #AI #startups